Iovance Grants Stock Options to 18 New Employees

SAN CARLOS, Calif., Sept. 18, 2026 /CourierPR/ -- Iovance Biotherapeutics, a biotechnology company focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has granted inducement stock options to eighteen new, non-executive employees. The grants, announced on September 17, 2026, cover an aggregate of 179,750 shares of the company’s common stock. These inducement stock options were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which is in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price of $10.02, the closing price of Iovance’s common stock on the date of grant. The options vest over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date, and the remaining shares vesting in eight quarterly installments over the next two years, subject to continued employment with the company.

Iovance Biotherapeutics, based in the United States, is the global leader in TIL cell therapies for solid tumors. The company’s flagship product, Amtagvi® (lifileucel), is the first FDA-approved, one-time treatment for previously treated advanced melanoma and is now approved in three global markets, available at more than 95 authorized treatment centers. The company’s TIL platform includes registrational trials and next-generation programs in additional solid tumors, such as gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches.

In a statement, the company emphasized its commitment to innovation and the development of advanced therapies for cancer patients.

The company’s forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially. These factors are detailed in the company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Iovance Biotherapeutics operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. The company’s commitment to innovation and patient care is reflected in its ongoing research and development efforts, as well as its expansion into new therapeutic areas.

The Amended and Restated 2021 Inducement Plan, which was used to grant these inducement stock options, is designed to attract and retain key personnel. The plan provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). This move underscores the company’s commitment to fostering a talented and dedicated workforce.